Transposagen Biopharmaceuticals, Inc. (“Transposagen”) is a leader in gene editing and integration technologies and services with applications in research & drug discovery, and bioproduction of therapeutic proteins and cells. Transposagen’s unique genome engineering capabilities allow for the creation of nearly any genetic modification in any genome.
Lonza America, Inc. (“Lonza”) acquired exclusive rights to Transposagen’s proprietary gene integration technology for the production of therapeutic proteins. Transposagen’s gene integration technology enable efficient production of high-titer cell lines that enable rapid and economical production of complex biological molecules
Transposagen’s gene integration assets will enhance Lonza’s service and product offering for cell-line development and bioproduction.
Crosstree Capital served as the sole advisor to Transposagen Biopharmaceuticals, Inc.